> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Abbott HeartMate 3 OK’d for Advanced Heart Failure
- URL: https://www.fdaweb.com/abbott-heartmate-3-okd-for-advanced-heart-failure/
- Published: 2018-10-19T12:00:00.000Z
- Updated: 2026-09-15T00:39:22.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5142630

FDA has approved Abbott’s HeartMate 3 Left Ventricular Assist Device (LVAD) as a destination therapy for people living with advanced heart failure. The device uses the company’s Full MagLev (fully magnetically-levitated) Flow, which reduces trauma to the blood passing through the pump while improving flow, the company says. Approval was supported by clinical data from the [MOMENTUM 3 trial](https://c212.net/c/link/?t=0&l=en&o=2273064-1&h=3026231455&u=http%3A%2F%2Fabbott.mediaroom.com%2F2018-03-11-New-Long-Term-Data-Show-Improved-Survival-and-Lower-Rates-of-Stroke-and-Pump-Thrombosis-for-Abbotts-HeartMate-3-Heart-Pump&a=MOMENTUM+3+trial&ref=fdaweb.com). During the study, patients with the device had a survival rate of 82.8% at two years. Additionally, the rates of suspected pump thrombosis were at 1.1% at two years. Abbott says the HeartMate 3 system includes the LVAD pump and other components that help power and monitor the technology including an external, wearable controller and battery system.